THTX Stock Summary and Trading Ideas (Theratechnologies - Common Shares | NASDAQ:THTX)

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

Theratechnologies - Common Shares trades on the NASDAQ stock market under the symbol THTX.

As of April 22, 2024, THTX stock price declined to $1.34 with 5,750 million shares trading.

THTX has a beta of 1.98, meaning it tends to be more sensitive to market movements. THTX has a correlation of 0.03 to the broad based SPY ETF.

THTX has a market cap of $61.61 million. This is considered a Micro Cap stock.

Last quarter Theratechnologies - Common Shares reported $16 million in Revenue and -$.10 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.02.

In the last 3 years, THTX stock traded as high as $17.84 and as low as $.88.

THTX has underperformed the market in the last year with a price return of -64.4% while the SPY ETF gained +22.3%. THTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -33.3% and -11.3%, respectively, while the SPY returned +3.9% and -3.6%, respectively.

THTX support price is $1.28 and resistance is $1.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that THTX stock will trade within this expected range on the day.